116
Articles Count
2195
Viewing Count
Elise Mak

A China observer

Chinook sets up China joint venture SanReno to tac...
Elise Mak · 9 hours ago
Kidney disease biotech Chinook Therapeutics has set up a joint venture called SanReno Therapeutics with an investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners Chinam, and more news from BeyondSpring, Everest, Zai Lab and ITabMed.
Further information
News
Cross-border biotech startup Zenas bets on in-lice...
Elise Mak · Yesterday
In-licensing and going global are the two topics discussed the most in China’s biotech industry today. Zenas BioPharma wants to prove that in-licensing can be a viable strategy when carried out carefully, and a cross-border setup from day one is the key to going global quickly, CEO Mu Hua told PharmaDJ.
Further information
Feature
Genetron taps AstraZeneca to fill void in MRD test...
Elise Mak · Yesterday
As current tests are not sophiscated enough to measure minimal residual disease (MRD) for solid tumors, precision oncology platform firm Genetron is aiming to develop next-generation sequencing (NGS)-based tumor-informed MRD tests together with AstraZeneca to fill the void in China.
Further information
Feature
Jemincare licenses out ex-China rights to KRAS inh...
Elise Mak · Yesterday
Shanghai Jemincare Pharmaceutical has signed a pact with HUYABIO to license out the exclusive worldwide ex-China rights to the KRAS inhibitor, JMKX1899, and more news from Hengrui, BeiGene and Neoantigen.
Further information
News
Abogen closes $300M Series C+ to take mRNA vaccine...
Elise Mak · 2 days ago
Suzhou Abogen Biosciences said it completed a Series C+ round to raise $300 million to accelerate the clinical development of its mRNA COVID-19 vaccine candidate and take it abroad faster, and more news from Sciwind, Ranok, Ablaze, Rorna, Keymed, Simcere and Genetron.
Further information
News
Primary Biotech closes angel round to build AI-ass...
Elise Mak · 3 days ago
Primary Biotech, established in 2020 in Changzhou, said it completed an angel round to expand its team, upgrade its technology platform and advance its pipeline, and more news from GSK/ViiV Healthcare and Junshi Biosciences.
Further information
News
Nhwa pays Lundbeck $18M to gain discarded schizoph...
Elise Mak · 6 days ago
Nhwa Pharmaceutical has licensed the Greater China rights to Lundbeck's Lu AF35700, an investigational drug for the treatment of schizophrenia in a deal worth up to RMB114.5 million ($18 million), and more news from Corregene, Ascentage and Alphamab.
Further information
News
BeiGene to build manufacturing and R&D center in N...
Elise Mak · 7 days ago
BeiGene announced plans to develop 42-acre site in New Jersey to house a new manufacturing campus and clinical R&D center, and more news from Walvax Bio, Boan Biotech and HUTCHMED.
Further information
News
Chinese drugmakers’ setbacks in capital market si...
Elise Mak · 7 days ago
Chinese regulators’ recent rejection of Shanghai HaiHe Pharmaceutical’s IPO on the STAR market casts doubts on the in-licensing model. Amid a market slump in the biotech sector, Chinese drugmakers need to think about innovation differently to win back investors’ confidence.
Further information
Feature
TenNor reports positive phase II results for hyper...
Elise Mak · 8 days ago
TenNor Therapeutics, of Suzhou, said it has generated positive top-line results for TNP-2092 from a phase II clinical trial for the treatment of hyperammonemiaor hepatic encephalopathy in patients with liver cirrhosis, and more news from Immunochina.
Further information
News
READ MORE

Personal Information

Copyright © 2016-2021 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement